Sucralfate
Identification
- Summary
Sucralfate is a gastro-duodenal protective agent used in the treatment of gastric and duodenal ulcers and to prevent duodenal ulcer recurrence.
- Brand Names
- Carafate, Sulcrate
- Generic Name
- Sucralfate
- DrugBank Accession Number
- DB00364
- Background
Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers Label, gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia 2. It is considered a cytoprotective agent, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances 2,13.
Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form 11,12.
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 1558.67
Monoisotopic: 1557.6045961 - Chemical Formula
- C12H35Al9O55S8
- Synonyms
- Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum
- Sucralfat
- Sucralfate
- Sucralfato
- Sucralfatum
- External IDs
- CGA-6J
- OS 202
Pharmacology
- Indication
The sucralfate suspension Label and tablet 15 are used for the treatment of active duodenal ulcer for up to 8 weeks. The tablet form may be used at a lower dose for healed duodenal ulcers, for the purpose of maintaining healing and preventing recurrence 13,15.
Sucralfate is also used in the prevention and/or treatment of gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia 2,13.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Dyspepsia ••• ••••• Prevention of Gerd (gastroesophageal reflux disease) ••• ••••• Used in combination to treat Gerd (gastroesophageal reflux disease) ••• ••••• Treatment of Gastric ulcer ••• ••••• Prevention of Gastritis ••• ••••• - Associated Therapies
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
This drug aids in the healing of duodenal ulcers, relieving painful inflammation by creating a protective mechanical barrier between the lining or skin of the gastrointestinal tract and damaging substances 2. In addition, sucralfate acts to increase levels of growth factors locally, and also causes an increase in prostaglandins which are important in the healing of the mucosa (lining) of the gastrointestinal tract 2.
- Mechanism of action
The mechanism of action of this drug in the healing duodenal ulcers is not yet completely defined, however, there are several probable mechanisms that adequately describe the healing activity of sucralfate. There is evidence that sucralfate acts locally to aid in tissue healing, and not systemically Label.
Studies in both humans and animals have indicated that sucralfate forms a complex that binds to protein-rich exudate found on the surface of ulcers. It binds to albumin and fibrinogen 7,8 preventing blood clot lysis by stomach acid (hydrochloric acid). Sucralfate increases the tissue levels of fibroblast growth factors and epidermal growth factors,5,6 leading to an increase in prostaglandins at the gastrointestinal tract lining, which promotes the healing of gastrointestinal ulcers.2
In the laboratory setting, a sucralfate-albumin film provides a barrier against the entry of hydrogen ions, which are a component of gastric acid. In humans, sucralfate, given at therapeutic doses for ulcers, decreases pepsin activity in gastric fluids by 32% Label. Pepsin has been shown to be damaging to tissues, further aggravating ulcer lesion inflammation 4. Bile salts have been implicated in mucosal injury to the gastrointestinal tract 9,10. Sucralfate has also been shown to adsorb bile salts in the laboratory, setting, which could further contribute to its beneficial effects in ulcer healing Label.
Target Actions Organism APepsin A-5 inhibitorHumans AFibroblast growth factor 2 agonistinducerHumans APro-epidermal growth factor inducerHumans UFibrinogen binderHumans - Absorption
This drug is absorbed from the gastrointestinal tract in very minimal quantities.Label The adsorbed sulfated disaccharide is excreted in the urine 13. This drug contains aluminum and after the administration of 1 g of sucralfate 4 times per day, about 0.001% to 0.017% of this aluminum content is absorbed in patients with normal renal function.13 This number is expected to increase in those with impaired renal function.13
- Volume of distribution
This drug is absorbed in a very small quantity, and normally localizes to inflamed gastrointestinal lesions Label.
- Protein binding
Sucralfate is bound to plasma proteins, especially albumin and transferrin 13.
- Metabolism
This drug is absorbed in very small quantities and is not significantly metabolized Label,13.
- Route of elimination
The negligible amount of this drug that is absorbed is excreted mainly in the urine within 48 hours Label,16.
- Half-life
The half-life is not known. In animals, the elimination half-life of the sucrose component of this drug is from 6-20 h 16.
- Clearance
Sucralfate contains aluminum. The administration of sucralfate in non-dialyzed chronic renal failure patients warrants careful consideration from the treating physician as the excretion of absorbed aluminum may be decreased, causing possible aluminum toxicity 13.
In dialyzed patients diagnosed with chronic renal failure, aluminum toxicity related to sucralfate has been observed and reported. The daily amount of aluminum ingestion (including sucralfate) should be carefully examined before administering sucralfate in combination with other drugs also containing aluminum, including various antacids 13.
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Overdose
Overdosage has never been observed with sucralfate 13. It is unlikely, as administering a maximum dose of up to 12 g/kg/body weight in several animal species did not result in death. The lethal dose could not be determined in these studies 13. It is likely that overdose of sucralfate in humans would result in constipation, and supportive treatment would be advised 13.
Use in pregnancy
This drug is considered a pregnancy Category B drug. Studies have been performed in rodents and rabbits at doses up to 50 times the recommended human dose. No harm to the fetus has been observed in the abovementioned studies. Sufficient and well-controlled clinical trials have not been performed in pregnant women. Due to the fact that the results of animal studies are not always relevant to human response, sucralfate should be used during pregnancy only if it is deemed essential for the mother's health Label.
Use in nursing
Whether this drug is excreted in human milk is currently unknown. Many drugs are excreted in breast milk, therefore, if sucralfate is administered to a lactating and nursing woman, caution should be observed Label.
Carcinogenesis
24 month toxicity studies were performed in rodents, and the dose of sucralfate reached up to 1 g/kg (equivalent to 12 times the recommended human dose). No signs of sucralfate-related tumors were notedLabel.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Sucralfate may decrease the excretion rate of Abacavir which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Sucralfate which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Sucralfate which could result in a higher serum level. Acenocoumarol The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Sucralfate. Acetaminophen Acetaminophen may decrease the excretion rate of Sucralfate which could result in a higher serum level. - Food Interactions
- Take on an empty stomach. Take at least 1 hour before or 2 hours after meals.
- Take separate from antacids. Take at least 30 minutes before or after antacids.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Images
- International/Other Brands
- Antepsin (Orion) / Sucramal (Menarini) / Sucraxol (Medifarma) / Ulcogant (Merck)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Carafate Tablet 1 g/1 Oral Allergan, Inc. 1981-10-30 Not applicable US Carafate Suspension 1 g/10mL Oral Physicians Total Care, Inc. 1996-03-12 Not applicable US Carafate Suspension 1 g/10mL Oral Allergan, Inc. 1993-12-16 Not applicable US Carafate Suspension 1 g/10mL Oral Atlantic Biologicals Corp. 1993-12-16 Not applicable US Sucralfate Suspension 1 g/10mL Oral Pharmaceutical Associates, Inc. 2009-11-19 2023-06-30 US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Apo-sucralfate - Tab 1g Tablet 1 g Oral Apotex Corporation 1994-12-31 Not applicable Canada Dom-sucralfate Tablet 1000 mg Oral Dominion Pharmacal 1999-09-15 2016-10-25 Canada Nu-sucralfate - Tab 1gm Tablet 1 g Oral Nu Pharm Inc 1994-12-31 2012-09-04 Canada PMS-sucralfate Tablet 1 g Oral Pharmascience Inc 1999-02-23 Not applicable Canada Sucralfate Tablet 1 g/1 Oral bryant ranch prepack 2020-02-17 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image APO-SUCRALFATE TABLET 1 g Tablet 1 g Oral PHARMAFORTE SINGAPORE PTE LTD 1996-02-27 Not applicable Singapore SUCRAL Tablet 500 mg Oral บริษัท โอลิค (ประเทศไทย) จำกัด 1998-12-04 Not applicable Thailand ซูคราเฟน Tablet 1000 mg Oral ห้างหุ้นส่วนจำกัด โรงงานเลิศสิงห์เภสัชกรรม 1995-08-16 Not applicable Thailand ซูเครทเจล Suspension 1000 mg/5ml Oral บริษัท นีโอ ฟาร์ม จำกัด จำกัด 2007-11-29 Not applicable Thailand อัลซีเฟต ชนิดยาน้ำแขวนตะกอน Suspension 1000 mg/5ml Oral บริษัท สยามเภสัช จำกัด 1990-08-17 Not applicable Thailand - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Varecell Intensive Liposome DoubleCream Sucralfate (0.18 g/100mL) + Adenosine (0.04 g/100mL) + Nicotinamide (2 g/100mL) Cream Topical D&S Cosmedique Co.Ltd. 2021-09-07 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Varecell Intensive Liposome DoubleCream Sucralfate (0.18 g/100mL) + Adenosine (0.04 g/100mL) + Nicotinamide (2 g/100mL) Cream Topical D&S Cosmedique Co.Ltd. 2021-09-07 Not applicable US
Categories
- ATC Codes
- A02BX02 — Sucralfate
- Drug Categories
- Alimentary Tract and Metabolism
- Aluminium Compounds
- Aluminum Complex
- Anti-Ulcer Agents
- Carbohydrates
- Drugs for Acid Related Disorders
- Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
- Drugs that are Mainly Renally Excreted
- Gastric Cytoprotectants
- Gastrointestinal Agents
- Glycosides
- Metal cations
- Metal divalent cations
- Organometallic Compounds
- Protectants
- Sulfur Compounds
- Thioglycosides
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- XX73205DH5
- CAS number
- 54182-58-0
- InChI Key
- IPLJAZDIICJQEL-JTJNLBSYSA-A
- InChI
- InChI=1S/C12H22O35S8.9Al.20H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;;20*1H2/q;9*+3;;;;;;;;;;;;;;;;;;;;/p-27/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m1............................./s1
- IUPAC Name
- [({[(2R,3R,4S,5R,6R)-6-{[(2S,3S,4R,5R)-3,4-bis({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)-2,5-bis[({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)methyl]oxolan-2-yl]oxy}-4,5-bis({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)-2-[({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)methyl]oxan-3-yl]oxy}sulfonyl)oxy]alumanediol alumanetriol hydrate
- SMILES
- O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O
References
- Synthesis Reference
Nick V. Lazaridis, Moo K. Park, Yousry Sayed, "Method for preparing high potency sucralfate." U.S. Patent US4990610, issued March, 1973.
US4990610- General References
- Rees WD: Mechanisms of gastroduodenal protection by sucralfate. Am J Med. 1991 Aug 8;91(2A):58S-63S. [Article]
- Candelli M, Carloni E, Armuzzi A, Cammarota G, Ojetti V, Pignataro G, Santoliquido A, Pola R, Pola E, Gasbarrini G, Gasbarrini A: Role of sucralfate in gastrointestinal diseases. Panminerva Med. 2000 Mar;42(1):55-9. [Article]
- Lam SK: Why do ulcers heal with sucralfate? Scand J Gastroenterol Suppl. 1990;173:6-16. [Article]
- Bardhan KD, Strugala V, Dettmar PW: Reflux revisited: advancing the role of pepsin. Int J Otolaryngol. 2012;2012:646901. doi: 10.1155/2012/646901. Epub 2011 Nov 10. [Article]
- Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [Article]
- Korman MG, Bolin TD, Szabo S, Hunt RH, Marks IN, Glise H: Sucralfate: the Bangkok review. J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):412-5. [Article]
- Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [Article]
- Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP: Clot lysis by gastric juice: an in vitro study. Gut. 1989 Dec;30(12):1704-7. [Article]
- Gadacz TR, Zuidema GD: Bile acid composition in patients with and without symptoms of postoperative refulx gastritis. Am J Surg. 1978 Jan;135(1):48-52. [Article]
- Duane WC, Wiegand DM: Mechanism by which bile salt disrupts the gastric mucosal barrier in the dog. J Clin Invest. 1980 Nov;66(5):1044-9. doi: 10.1172/JCI109932. [Article]
- FDA approval, Sucralfate suspension [Link]
- Sucralfate tablet FDA approval [Link]
- Product monograph, Sulcrate [File]
- MedSafe NZ, Sucralfate [File]
- Sucralfate FDA label, tablet form [File]
- Risk profile of sucralfate [File]
- External Links
- Human Metabolome Database
- HMDB0014508
- KEGG Compound
- C07314
- PubChem Compound
- 70789197
- PubChem Substance
- 46508862
- ChemSpider
- 32701653
- 10156
- ChEMBL
- CHEMBL2029132
- PharmGKB
- PA451524
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Sucralfate
- FDA label
- Download (217 KB)
- MSDS
- Download (73.6 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Antimicrobial Drug Susceptibility Pattern / Etiological Organisms / Stress Ulcer Prophylaxis / Ventilator Associated Bacterial Pneumonia (VABP) 1 4 Completed Treatment Chronic Erosive Gastritis 1 4 Completed Treatment Chronic Radiation Proctitis 1 4 Completed Treatment Dyspepsia 1 3 Completed Supportive Care Head And Neck Cancer / Mucositis 1
Pharmacoeconomics
- Manufacturers
- Axcan pharma us inc
- Nostrum laboratories inc
- Teva pharmaceuticals usa inc
- Packagers
- Amerisource Health Services Corp.
- Amneal Pharmaceuticals
- A-S Medication Solutions LLC
- Axcan Pharma Inc.
- Bryant Ranch Prepack
- Cardinal Health
- Caremark LLC
- Dept Health Central Pharmacy
- Direct Dispensing Inc.
- Diversified Healthcare Services Inc.
- Eon Labs
- Giant Food Inc.
- Golden State Medical Supply Inc.
- H.J. Harkins Co. Inc.
- Heartland Repack Services LLC
- Ivax Pharmaceuticals
- Levista Inc.
- Long Wing International Inc.
- Major Pharmaceuticals
- Mckesson Corp.
- Medisca Inc.
- Merckle GmbH
- Murfreesboro Pharmaceutical Nursing Supply
- Nostrum Laboratories Inc.
- Nucare Pharmaceuticals Inc.
- PD-Rx Pharmaceuticals Inc.
- Pharmaceutical Association
- Pharmaceutical Utilization Management Program VA Inc.
- Pharmedix
- Physicians Total Care Inc.
- Prasco Labs
- Precision Dose Inc.
- Prepak Systems Inc.
- Prescript Pharmaceuticals
- Prime European Therapeuticals SPA
- Qingdao Pana Life Biochem Co. Ltd.
- Resource Optimization and Innovation LLC
- Sandhills Packaging Inc.
- Sanofi-Aventis Inc.
- Stat Rx Usa
- Teva Pharmaceutical Industries Ltd.
- UDL Laboratories
- Vangard Labs Inc.
- Vistapharm Inc.
- Warrick Pharmaceuticals Corp.
- Watson Pharmaceuticals
- Xactdose Inc.
- Dosage Forms
Form Route Strength Tablet Oral 1000.00 mg Tablet, chewable Buccal 500 mg Powder Oral 1 G Powder Oral 2 G Suspension Oral 20 % Tablet, soluble Oral 1000 mg Suspension Oral 1 g/5ml Tablet Oral 1 g Tablet, coated Oral Gel Oral Granule, for suspension Oral 1 g Granule, for suspension Oral 2 G Tablet, chewable Oral 1 G Suspension Oral 2000000 g Tablet, chewable Oral 1000 mg Tablet Oral 1.000 g Suspension Oral 500 MG/5ML Suspension Oral 500 MG Tablet Oral 1000.000 mg Tablet Oral Suspension Oral 1000.00 mg Tablet Oral 1.0 g Tablet Oral 500 mg Suspension Oral Suspension Oral 1 g/10mL Tablet Oral 1 g/1 Powder Not applicable 1 kg/1kg Tablet Oral 1.11 mg Suspension Oral 20 g Powder, for suspension Oral 1 G Powder, for suspension Oral 2 G Powder, for suspension Oral Granule Oral 1 g Gel Oral 1 G/5ML Gel Oral 2 G/10ML Granule, for solution Oral 1 g Granule, for suspension Oral Tablet, chewable Oral Tablet, coated Oral 1000 mg Suspension Oral 100 mg / mL Suspension Oral 1 g / 5 mL Granule Oral Tablet Oral Tablet Oral 1.0000 g Suspension Oral 20.000 g Tablet Oral 1062.500 mg Cream Topical Tablet Oral 1000 mg Suspension Oral 1000 mg/5ml Tablet, chewable Oral 500 mg - Prices
Unit description Cost Unit Sucralfate 1 gm/10ml Suspension 10ml Cup 13.99USD cup Carafate 1 gm tablet 1.45USD tablet Sucralfate 1 gm tablet 0.72USD tablet Sucralfate powder 0.6USD g Sulcrate 1 g Tablet 0.59USD tablet Apo-Sucralfate 1 g Tablet 0.31USD tablet Novo-Sucralate 1 g Tablet 0.31USD tablet Nu-Sucralfate 1 g Tablet 0.31USD tablet Pms-Sucralfate 1 g Tablet 0.31USD tablet Carafate 1 gm/10ml Suspension 0.24USD ml Sulcrate Suspension Plus 200 mg/ml Suspension 0.11USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) >220 https://www.trc-canada.com/product-detail/?S692350 water solubility Insoluble https://www.chemicalbook.com/ChemicalProductProperty_US_CB6239042.aspx logP -7.087 http://www.molbase.com/en/overview_54182-58-0-moldata-62765.html pKa 0.43 to 1.19 https://www.chemicalbook.com/ChemicalProductProperty_US_CB6239042.aspx - Predicted Properties
Property Value Source Water Solubility 0.774 mg/mL ALOGPS logP 0.74 ALOGPS logP -5.9 Chemaxon logS -3.3 ALOGPS pKa (Strongest Acidic) 13.53 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 35 Chemaxon Hydrogen Donor Count 16 Chemaxon Polar Surface Area 772.17 Å2 Chemaxon Rotatable Bond Count 37 Chemaxon Refractivity 180.03 m3·mol-1 Chemaxon Polarizability 107.19 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.7959 Blood Brain Barrier + 0.8803 Caco-2 permeable - 0.6433 P-glycoprotein substrate Non-substrate 0.8087 P-glycoprotein inhibitor I Non-inhibitor 0.5656 P-glycoprotein inhibitor II Non-inhibitor 0.986 Renal organic cation transporter Non-inhibitor 0.8471 CYP450 2C9 substrate Non-substrate 0.8611 CYP450 2D6 substrate Non-substrate 0.8256 CYP450 3A4 substrate Non-substrate 0.6233 CYP450 1A2 substrate Non-inhibitor 0.772 CYP450 2C9 inhibitor Non-inhibitor 0.8211 CYP450 2D6 inhibitor Non-inhibitor 0.8865 CYP450 2C19 inhibitor Non-inhibitor 0.7869 CYP450 3A4 inhibitor Non-inhibitor 0.9828 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9328 Ames test Non AMES toxic 0.5805 Carcinogenicity Non-carcinogens 0.5356 Biodegradation Not ready biodegradable 0.8432 Rat acute toxicity 2.4219 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7937 hERG inhibition (predictor II) Non-inhibitor 0.8793
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Shows particularly broad specificity; although bonds involving phenylalanine and leucine are preferred, many others are also cleaved to some extent.
- Specific Function
- Aspartic-type endopeptidase activity
- Gene Name
- PGA5
- Uniprot ID
- P0DJD9
- Uniprot Name
- Pepsin A-5
- Molecular Weight
- 41992.845 Da
References
- Jensen SL, Funch Jensen P: Role of sucralfate in peptic disease. Dig Dis. 1992;10(3):153-61. [Article]
- Hollander D, Tarnawski A: The protective and therapeutic mechanisms of sucralfate. Scand J Gastroenterol Suppl. 1990;173:1-5. [Article]
- Peterson WL: Pathogenesis and therapy of peptic ulcer disease. J Clin Gastroenterol. 1990;12 Suppl 2:S1-6. [Article]
- Kegg [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- AgonistInducer
- General Function
- Ligand-dependent nuclear receptor transcription coactivator activity
- Specific Function
- Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
- Gene Name
- FGF2
- Uniprot ID
- P09038
- Uniprot Name
- Fibroblast growth factor 2
- Molecular Weight
- 30769.715 Da
References
- Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [Article]
- Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ: Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl. 1995;210:9-14. [Article]
- Szabo S, Kusstatscher S, Sakoulas G, Sandor Z, Vincze A, Jadus M: Growth factors: new 'endogenous drugs' for ulcer healing. Scand J Gastroenterol Suppl. 1995;210:15-8. [Article]
- Korman MG, Bolin TD, Szabo S, Hunt RH, Marks IN, Glise H: Sucralfate: the Bangkok review. J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):412-5. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inducer
- General Function
- Transmembrane receptor protein tyrosine kinase activator activity
- Specific Function
- EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in ...
- Gene Name
- EGF
- Uniprot ID
- P01133
- Uniprot Name
- Pro-epidermal growth factor
- Molecular Weight
- 133993.12 Da
References
- Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ: Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl. 1995;210:9-14. [Article]
- Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [Article]
- Konturek SJ: Role of growth factors in gastroduodenal protection and healing of peptic ulcers. Gastroenterol Clin North Am. 1990 Mar;19(1):41-65. [Article]
References
- Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [Article]
- Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP: Clot lysis by gastric juice: an in vitro study. Gut. 1989 Dec;30(12):1704-7. [Article]
- Sucralfate - Drug Summary [Link]
Drug created at June 13, 2005 13:24 / Updated at May 19, 2024 10:11